— the granting of forest management permits (other than permits for the supply of wood processing plants and for a punctual activity referred to in section 24.1 of the Act which are not applicable in public forest reserves);

— the management of public forest reserves and the sale of timber;

— the conclusion of forest management agreements;

— the granting of permits or authorizations for the construction of forest roads;

— control of the access to forest roads in cases of fire, in the thaw period or for safety reasons;

— prescribing forest management standards, in accordance with the Regulation respecting standards of forest management for forests in the public domain or with any other standards authorized under the Forest Act;

— the collection of dues payable by holders of authorizations, permits or rights granted by the RCM's under the applicable regulations;

— the supervision and control of forest management activities, in accordance with the Forest Act and the regulations thereunder.

IN THE FIELD OF LAND REGULATIONS

Within the framework of the experimental delegation of land regulations, the RCM's will be authorized to adopt regulations on the following matters:

— the conditions and rules for computing prices, rentals, fees or other costs regarding sales, leases, exchanges, gratuitous transfers, occupation licences or the granting of any other right;

— the norms and conditions under which persons may have access to and stay on land and the circumstances under which access to or staying on the land may be prohibited, while preserving the right of every person to pass through lands in the public domain covered by a delegation;

— the conditions and circumstances under which authorization is not required to erect or maintain a building, installations or works on land otherwise than in the exercising of a right or the performing of a duty imposed by law;

— norms respecting the location, construction, maintenance and use of roads other than forest or mining roads;

— norms respecting the right to use the roads referred to in the preceding paragraph for the safety of users and the protection of roads.

1339

O.C. 431-97, 26 March 1997

An Act respecting prescription drug insurance and amending various legislative provisions (1996, c. 32)

Basic prescription drug insurance plan
— Regulation
— Amendment

Regulation to amend the Regulation respecting the basic prescription drug insurance plan

WHEREAS under subparagraph 3 of the first paragraph of section 78 of the Act respecting prescription drug insurance and amending various legislative provisions (1996, c. 32), the Government may, after consulting the Régie de l'assurance-maladie du Québec, make regulations to determine the cases, conditions and therapeutic indications in and for which the cost of certain medications included in the list drawn up by the Minister under section 60 of the Act is covered by the basic plan; the conditions may vary according to whether the coverage is provided by the Board or under a group insurance contract or an employee benefit plan;

WHEREAS under section 79 of the Act, such a regulation is not subject to the requirements concerning publication and date of coming into force contained in sections 8 and 17 of the Regulations Act (R.S.Q., c. R-18.1);

WHEREAS the Government made the Regulation respecting the basic prescription drug insurance plan by Order in Council 1519-96 dated 4 December 1996;

WHEREAS it is expedient to amend the Regulation;

WHEREAS in accordance with section 78 of the Act respecting prescription drug insurance and amending various legislative provisions, the Régie de l'assurance-maladie du Québec has been consulted;

IT IS ORDERED, therefore, upon the recommendation of the Minister of Health and Social Services:

THAT the Regulation to amend the Regulation respecting the basic prescription drug insurance plan, attached to this Order in Council, be made.

MICHEL CARPENTIER,
Clerk of the Conseil exécutif

Regulation to amend the Regulation respecting the basic prescription drug insurance plan

An Act respecting prescription drug insurance and amending various legislative provisions (1996, c. 32, s. 78. 1st par., subpar. 3)

1. The Regulation respecting the basic prescription drug insurance plan, made by Order in Council 1519-96 dated 4 December 1996 and amended by the Regulations made by Orders in Council 1532-96 dated 6 December 1996 and 364-97 dated 19 March 1997, is further amended, in the first paragraph of section 2.1, by substituting the words "first paragraph of section 8" for the words "second paragraph of section 8".

2. The Regulation is amended, in the second paragraph of section 2.1,

(1) by striking out paragraph 6;

(2) by inserting the following after paragraph 13:

"(13.1) CARVEDILOL tab., Coreg: for the treatment of stable symptomatic congestive heart failure in patients receiving a diuretic and an angiotensin converting enzyme inhibitor;";

(3) by inserting the following after paragraph 20:

"(20.1) DIHYDROERGOTAMINE (mesylate) nasal spray, Migranal: for the treatment of nonprophylactic episodes of migraines in patients for whom treatment with analgesics or with other drug therapies is ineffective;";

(4) by substituting the following for paragraph 29:

"(29) FAMCICLOVIR tab., Famvir:

(a) for the early treatment of zona, that is, within 48 to 72 after the appearance of lesions;

(b) for the curative treatment of severe infectious episodes of recurring genital herpes;";

(5) by substituting, in paragraph 47 of the English version, the words "even if they require assistance" for the words "although with assistance";

(6) by inserting the following after paragraph 72:

"(72.1) SOMATREM inj. pd., Protropin:

(a) for the treatment of children suffering from delayed growth caused by insufficient secretion of the endogenous growth hormone, except children who are carriers of a Turner's syndrome or are suffering from achondroplasia or from delayed growth of a genetic or familial type, children whose bone age has reached 15 years for girls and 16 years for boys, and children whose growth rate falls below 4 cm per year, evaluated on two consecutive visits at a 3-month interval, where they meet the following criteria:

i. unterminated growth and growth rate for their bone age less than the 25th percentile, calculated over at least a one-year period; the one-year observation period does not apply to young children suffering from hypoglycemia secondary to a growth hormone deficiency;

ii. serum concentration of somatotrophin less than 8 ng/mL measured by two pharmacological tests, or serum concentration between 8 and 10 ng/mL if the tests are repeated twice at a 6-month interval;

(b) for the treatment of children suffering from delayed growth related to chronic renal failure until renal transplant;"; and

(7) by substituting the following for paragraph 77:

"(77) VALACYCLOVIR (hydrochloride) tab., Valtrex:

(a) for the early treatment of zona, that is, within 48 to 72 hours after the appearance of lesions;

(b) for the curative treatment of severe infectious episodes of recurring genital herpes.".

3. This Regulation comes into force on 7 April 1997.

1350